211 related articles for article (PubMed ID: 31812152)
1. Orally consumed cannabinoids provide long-lasting relief of allodynia in a mouse model of chronic neuropathic pain.
Abraham AD; Leung EJY; Wong BA; Rivera ZMG; Kruse LC; Clark JJ; Land BB
Neuropsychopharmacology; 2020 Jun; 45(7):1105-1114. PubMed ID: 31812152
[TBL] [Abstract][Full Text] [Related]
2. Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model.
Mitchell VA; Harley J; Casey SL; Vaughan AC; Winters BL; Vaughan CW
Neuropharmacology; 2021 May; 189():108529. PubMed ID: 33741405
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination.
Linher-Melville K; Zhu YF; Sidhu J; Parzei N; Shahid A; Seesankar G; Ma D; Wang Z; Zacal N; Sharma M; Parihar V; Zacharias R; Singh G
PLoS One; 2020; 15(6):e0234176. PubMed ID: 32497151
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal Actions of the Cannabis Constituents Δ(9)-Tetrahydrocannabinol and Cannabidiol in a Mouse Neuropathic Pain Model.
Casey SL; Mitchell VA; Sokolaj EE; Winters BL; Vaughan CW
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955774
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations.
Moore CF; Weerts EM
Psychopharmacology (Berl); 2022 May; 239(5):1397-1408. PubMed ID: 34652500
[TBL] [Abstract][Full Text] [Related]
6. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain.
Hoggart B; Ratcliffe S; Ehler E; Simpson KH; Hovorka J; Lejčko J; Taylor L; Lauder H; Serpell M
J Neurol; 2015 Jan; 262(1):27-40. PubMed ID: 25270679
[TBL] [Abstract][Full Text] [Related]
7. Cannabis constituent synergy in a mouse neuropathic pain model.
Casey SL; Atwal N; Vaughan CW
Pain; 2017 Dec; 158(12):2452-2460. PubMed ID: 28885457
[TBL] [Abstract][Full Text] [Related]
8. THC and gabapentin interactions in a mouse neuropathic pain model.
Atwal N; Casey SL; Mitchell VA; Vaughan CW
Neuropharmacology; 2019 Jan; 144():115-121. PubMed ID: 30312630
[TBL] [Abstract][Full Text] [Related]
9. Vaporized cannabis extract-induced antinociception in male vs female rats with persistent inflammatory pain.
Craft RM; Gogulski HY; Freels TG; Glodosky NC; McLaughlin RJ
Pain; 2023 Sep; 164(9):2036-2047. PubMed ID: 37027147
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol and Delta-9-Tetrahydrocannabinol Interactions in Male and Female Rats With Persistent Inflammatory Pain.
Britch SC; Craft RM
J Pain; 2023 Jan; 24(1):98-111. PubMed ID: 36122809
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol enhances the antinociceptive effects of morphine and attenuates opioid-induced tolerance in the chronic constriction injury model.
Jesus CHA; Ferreira MV; Gasparin AT; Rosa ES; Genaro K; Crippa JAS; Chichorro JG; Cunha JMD
Behav Brain Res; 2022 Oct; 435():114076. PubMed ID: 36028000
[TBL] [Abstract][Full Text] [Related]
12. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
Filippini G; Minozzi S; Borrelli F; Cinquini M; Dwan K
Cochrane Database Syst Rev; 2022 May; 5(5):CD013444. PubMed ID: 35510826
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal.
Li AL; Lin X; Dhopeshwarkar AS; Thomaz AC; Carey LM; Liu Y; Nikas SP; Makriyannis A; Mackie K; Hohmann AG
Mol Pharmacol; 2019 Feb; 95(2):155-168. PubMed ID: 30504240
[TBL] [Abstract][Full Text] [Related]
14. Effect of cannabidiolic acid and ∆
Rock EM; Limebeer CL; Parker LA
Psychopharmacology (Berl); 2018 Nov; 235(11):3259-3271. PubMed ID: 30225659
[TBL] [Abstract][Full Text] [Related]
15. Antinociceptive and Immune Effects of Delta-9-Tetrahydrocannabinol or Cannabidiol in Male Versus Female Rats with Persistent Inflammatory Pain.
Britch SC; Goodman AG; Wiley JL; Pondelick AM; Craft RM
J Pharmacol Exp Ther; 2020 Jun; 373(3):416-428. PubMed ID: 32179573
[TBL] [Abstract][Full Text] [Related]
16. Median Nerve Stimulation as a Nonpharmacological Approach to Bypass Analgesic Tolerance to Morphine: A Proof-of-Concept Study in Mice.
Lee MT; Chen YH; Mackie K; Chiou LC
J Pain; 2021 Mar; 22(3):300-312. PubMed ID: 33069869
[TBL] [Abstract][Full Text] [Related]
17. Distinct antinociceptive and conditioned behavioral effects are produced by individual cannabinoids and a cannabis-derived mixture.
Morris T; Cucinello-Ragland JA; Marks TJ; Prevost K; Glenn JF; Davenport GJ; Edwards S; Winsauer PJ
Pharmacol Biochem Behav; 2024 Feb; 235():173692. PubMed ID: 38128766
[TBL] [Abstract][Full Text] [Related]
18. Single and combined effects of Δ
King KM; Myers AM; Soroka-Monzo AJ; Tuma RF; Tallarida RJ; Walker EA; Ward SJ
Br J Pharmacol; 2017 Sep; 174(17):2832-2841. PubMed ID: 28548225
[TBL] [Abstract][Full Text] [Related]
19. Ultralow dose fentanyl prevents development of chronic neuropathic pain in rats.
Wala EP; Holtman JR; Sloan PA
J Opioid Manag; 2013; 9(2):85-96. PubMed ID: 23709318
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside.
Rahn EJ; Hohmann AG
Neurotherapeutics; 2009 Oct; 6(4):713-37. PubMed ID: 19789075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
